title: Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome?
authors.forename: Olivier
authors.initials: O
authors.lastname: Mir
authors.forename: Luc
authors.initials: L
authors.lastname: Mouthon
authors.forename: Jérôme
authors.initials: J
authors.lastname: Alexandre
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Mallion
authors.forename: Gilbert
authors.initials: G
authors.lastname: Deray
authors.forename: Loïc
authors.initials: L
authors.lastname: Guillevin
authors.forename: François
authors.initials: F
authors.lastname: Goldwasser
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D050197:Atherosclerosis / Q000150:complications; D000068258:Bevacizumab; D017700:Embolism, Cholesterol / Q000139:chemically induced / Q000209:etiology*; D004802:Eosinophilia / Q000150:complications*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced* / Q000150:complications; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D011446:Prospective Studies; D013577:Syndrome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab